Impact of hydroxychloroquine on disease progression and ICU admissions in patients with SARS-CoV-2 infection

{ 'indexed': {'date-parts': [[2024, 3, 30]], 'date-time': '2024-03-30T16:30:36Z', 'timestamp': 1711816236673}, 'reference-count': 19, 'publisher': 'Oxford University Press (OUP)', 'issue': '8', 'content-domain': {'domain': [], 'crossmark-restriction': False}, 'published-print': {'date-parts': [[2021, 3, 31]]}, 'abstract': '<jats:title>Abstract</jats:title>\n' ' <jats:sec>\n' ' <jats:title>Purpose</jats:title>\n' ' <jats:p>To evaluate whether use of hydroxychloroquine was associated with a ' 'reduced likelihood of intensive care unit (ICU) admission in patients with coronavirus ' 'disease 2019 (COVID-19) in the early weeks of the pandemic.</jats:p>\n' ' </jats:sec>\n' ' <jats:sec>\n' ' <jats:title>Methods</jats:title>\n' ' <jats:p>A retrospective, observational cohort study was conducted to ' 'determine selected treatment outcomes in 336 patients hospitalized with COVID-19 at an acute ' 'care community hospital in the Hudson Valley region of New York from March 20 to April 20, ' '2020. Eligibility included admission to the hospital, a laboratory-confirmed diagnosis of ' 'SARS-CoV-2 infection, and no need for intubation or intensive care at admission. The median ' '(interquartile range) ages of patients who received hydroxychloroquine (n = 188) and those ' 'who did not (n = 148) were 68 (58-82) and 64 (51-73) years, respectively. In a multivariable ' 'model that included age, gender, obesity, diabetes, and hydroxychloroquine use, patients who ' 'received hydroxychloroquine were significantly more likely than those not treated with the ' 'drug to be transferred to an ICU (odds ratio, [OR], 8.1; 95% confidence interval [CI]: ' '3.8-17) and significantly more likely to be intubated (OR, 7.99; 95% CI, 3.76-16.91); these ' 'associations were not influenced by disease severity. In-hospital mortality did not differ ' 'significantly with disease severity between those who did and those who did not receive ' 'hydroxychloroquine.</jats:p>\n' ' </jats:sec>\n' ' <jats:sec>\n' ' <jats:title>Conclusion</jats:title>\n' ' <jats:p>Hydroxychloroquine use was significantly associated with increased ' 'risks of ICU admission and intubation in patients with mild, moderate, and severe symptoms of ' 'COVID-19. There were no significant between-group differences in mortality with use vs nonuse ' 'of hydroxychloroquine.</jats:p>\n' ' </jats:sec>', 'DOI': '10.1093/ajhp/zxab056', 'type': 'journal-article', 'created': {'date-parts': [[2021, 2, 18]], 'date-time': '2021-02-18T14:26:48Z', 'timestamp': 1613658408000}, 'page': '689-696', 'source': 'Crossref', 'is-referenced-by-count': 7, 'title': 'Impact of hydroxychloroquine on disease progression and ICU admissions in patients with ' 'SARS-CoV-2 infection', 'prefix': '10.1093', 'volume': '78', 'author': [ { 'given': 'Nirvana', 'family': 'Awad', 'sequence': 'first', 'affiliation': [{'name': 'Montefiore Nyack Hospital, Nyack, NY, USA'}]}, { 'given': 'Daryl S', 'family': 'Schiller', 'sequence': 'additional', 'affiliation': [{'name': 'Montefiore Nyack Hospital, Nyack, NY, USA'}]}, { 'given': 'Magda', 'family': 'Fulman', 'sequence': 'additional', 'affiliation': [{'name': 'Montefiore Nyack Hospital, Nyack, NY, USA'}]}, { 'given': 'Azfar', 'family': 'Chak', 'sequence': 'additional', 'affiliation': [{'name': 'Montefiore Nyack Hospital, Nyack, NY, USA'}]}], 'member': '286', 'published-online': {'date-parts': [[2021, 2, 18]]}, 'reference': [ {'key': '2021033109414455300_CIT0001', 'author': 'Johns Hopkins University & Medicine'}, { 'key': '2021033109414455300_CIT0002', 'author': 'Centers for Disease Control and Prevention'}, { 'key': '2021033109414455300_CIT0003', 'doi-asserted-by': 'crossref', 'first-page': '1', 'DOI': '10.1186/1743-422X-2-69', 'article-title': 'Chloroquine is a potent inhibitor of SARS coronavirus infection and ' 'spread', 'volume': '2', 'author': 'Vincent', 'year': '2005', 'journal-title': 'Virol J.'}, {'key': '2021033109414455300_CIT0004', 'author': 'Bhimraj', 'year': '2020'}, { 'key': '2021033109414455300_CIT0005', 'doi-asserted-by': 'crossref', 'first-page': '145', 'DOI': '10.1007/s12016-010-8243-x', 'article-title': 'Hydroxychloroquine: from malaria to autoimmunity', 'volume': '42', 'author': 'Ben-Zvi', 'year': '2012', 'journal-title': 'Clinic Rev Allerg Immunol.'}, { 'key': '2021033109414455300_CIT0006', 'doi-asserted-by': 'crossref', 'first-page': '144', 'DOI': '10.1186/1475-2875-10-144', 'article-title': 'Quinine, an old anti-malarial drug in a modern world: role in the ' 'treatment of malaria', 'volume': '10', 'author': 'Achan', 'year': '2011', 'journal-title': 'Malar J.'}, { 'key': '2021033109414455300_CIT0007', 'doi-asserted-by': 'crossref', 'DOI': '10.1016/j.mayocp.2020.03.024', 'article-title': 'Urgent guidance for navigating and circumventing the QTc-prolonging and ' 'torsadogenic potential of possible pharmacotherapies for coronavirus ' 'disease 19 (COVID-19)', 'author': 'Giudicessi', 'year': '2020', 'journal-title': 'Mayo Clin Proc.'}, { 'issue': '10', 'key': '2021033109414455300_CIT0008', 'doi-asserted-by': 'crossref', 'first-page': '1199', 'DOI': '10.1001/jamaophthalmol.2014.1720', 'article-title': 'Are long-term chloroquine or hydroxychloroquine users being checked ' 'regularly for toxic maculopathy?', 'volume': '132', 'author': 'Nika', 'year': '2014', 'journal-title': 'JAMA Ophthalmol'}, { 'issue': '15', 'key': '2021033109414455300_CIT0009', 'doi-asserted-by': 'crossref', 'first-page': '732', 'DOI': '10.1093/cid/ciaa237', 'article-title': 'In vitro antiviral activity and projection of optimized dosing design ' 'of hydroxychloroquine for the treatment of severe acute respiratory ' 'syndrome coronavirus 2', 'volume': '71', 'author': 'Yao', 'year': '2020', 'journal-title': 'Clin Infect Dis.'}, { 'key': '2021033109414455300_CIT0010', 'doi-asserted-by': 'crossref', 'DOI': '10.1093/cid/ciaa394', 'article-title': 'Towards optimization of hydroxychloroquine dosing in intensive care ' 'unit COVID-19 patients', 'author': 'Perinel', 'year': '2020', 'journal-title': 'Clin Infect Dis'}, {'key': '2021033109414455300_CIT0011', 'author': 'Downes', 'year': '2020'}, { 'key': '2021033109414455300_CIT0012', 'doi-asserted-by': 'crossref', 'first-page': '335', 'DOI': '10.1186/cc1521', 'article-title': 'Statistics review 4: sample size calculations', 'volume': '6', 'author': 'Whitley', 'year': '2002', 'journal-title': 'Critical Care'}, { 'issue': '25', 'key': '2021033109414455300_CIT0013', 'doi-asserted-by': 'crossref', 'first-page': '2411', 'DOI': '10.1056/NEJMoa2012410', 'article-title': 'Observational study of hydroxychloroquine in hospitalized patients with ' 'COVID-19', 'volume': '382', 'author': 'Geleris', 'year': '2020', 'journal-title': 'N Engl J Med.'}, { 'key': '2021033109414455300_CIT0014', 'doi-asserted-by': 'crossref', 'DOI': '10.1001/jama.2020.8630', 'article-title': 'Association of treatment with hydroxychloroquine or azithromycin with ' 'in-hospital mortality in patients with COVID-19 in New York State', 'author': 'Rosenberg', 'year': '2020', 'journal-title': 'JAMA.'}, { 'key': '2021033109414455300_CIT0015', 'doi-asserted-by': 'crossref', 'DOI': '10.1001/jama.2020.22240', 'article-title': 'Effect of hydroxychloroquine on clinical status at 14 days in ' 'hospitalized patients with COVID-19: a randomized clinical trial', 'author': 'Self', 'year': '2020', 'journal-title': 'JAMA.'}, { 'key': '2021033109414455300_CIT0016', 'article-title': 'Hydroxychloroquine in patients with COVID-19: an open-label, ' 'randomized, controlled trial', 'author': 'Tang', 'year': '2020', 'journal-title': 'medRxiv'}, { 'key': '2021033109414455300_CIT0017', 'article-title': 'Efficacy of hydroxychloroquine in patients with COVID-19: results of a ' 'randomized clinical trial', 'author': 'Chen', 'year': '2020', 'journal-title': 'medRxiv'}, { 'key': '2021033109414455300_CIT0018', 'article-title': 'Outcomes of hydroxychloroquine usage in United States veterans ' 'hospitalized with COVID-19', 'author': 'Magagnoli', 'year': '2020', 'journal-title': 'medRxiv'}, { 'key': '2021033109414455300_CIT0019', 'doi-asserted-by': 'crossref', 'DOI': '10.1056/NEJMoa2002032', 'article-title': 'Clinical characteristics of coronavirus disease 2019 in China', 'author': 'Guan', 'year': '2020', 'journal-title': 'N Engl J Med.'}], 'container-title': 'American Journal of Health-System Pharmacy', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'http://academic.oup.com/ajhp/advance-article-pdf/doi/10.1093/ajhp/zxab056/36314759/zxab056.pdf', 'content-type': 'application/pdf', 'content-version': 'am', 'intended-application': 'syndication'}, { 'URL': 'http://academic.oup.com/ajhp/article-pdf/78/8/689/36808218/zxab056.pdf', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'syndication'}, { 'URL': 'http://academic.oup.com/ajhp/article-pdf/78/8/689/36808218/zxab056.pdf', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2021, 3, 31]], 'date-time': '2021-03-31T10:01:40Z', 'timestamp': 1617184900000}, 'score': 1, 'resource': {'primary': {'URL': 'https://academic.oup.com/ajhp/article/78/8/689/6144083'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2021, 2, 18]]}, 'references-count': 19, 'journal-issue': { 'issue': '8', 'published-online': {'date-parts': [[2021, 2, 18]]}, 'published-print': {'date-parts': [[2021, 3, 31]]}}, 'URL': 'http://dx.doi.org/10.1093/ajhp/zxab056', 'relation': {}, 'ISSN': ['1079-2082', '1535-2900'], 'subject': ['Health Policy', 'Pharmacology'], 'published-other': {'date-parts': [[2021, 4, 15]]}, 'published': {'date-parts': [[2021, 2, 18]]}}